The American Society for Radiation Oncology (ASTRO) issued new guidance on using radiation therapy to treat grade 4 diffuse gliomas, which account for nearly half of malignant brain tumors in adults ...

The FDA removed the Risk Evaluation and Mitigation Strategies (REMS) requirements for approved BCMA- and CD19-targeting chimeric antigen receptor (CAR) T-cell therapies. The FDA can require a REMS ...

The NIH will, for now, not cancel additional research grants beyond those that have already been terminated, according to an internal memo from a senior NIH official informing agency staff of the ...

AbstractPurpose:. Melanoma brain metastases (MBM) are common in advanced melanoma and linked to poor prognosis. Preventing MBM can improve survival and reduce morbidity. Although dual-agent ...

The FDA gave accelerated approval to datopotamab deruxtecan (Datroway; Daiichi Sankyo), a TROP-2 targeting antibody–drug conjugate (ADC), for patients with advanced or metastatic EGFR-mutated ...

Major Finding: An intraoperative sequencing workflow provides rapid turnaround of comprehensive molecular profiling of central nervous system (CNS) tumors. Concept: Methylation profile and DNA copy ...

Major Finding: Uptake of exogenous lipoproteins through glycosaminoglycans protects cancer cells from ferroptosis.Concept: Lipoproteins inhibit ferroptosis by delivering α-tocopherol, a form of ...

First Disclosures First Disclosures in Molecular Cancer Therapeutics present drugs for the first time in published literature, accompanied by pertinent translational investigations. Submissions are ...

AbstractImmune checkpoint blockade (ICB) has revolutionized cancer treatment. Unfortunately, the inability of lymphocytes to infiltrate the tumor nest, a phenomenon known as immune exclusion, ...

In two observational studies that included more than 170,000 and 86,000 patients, respectively, with obesity and/or diabetes, researchers found that glucagon-like–peptide (GLP)-1 receptor agonists may ...

AbstractImmune checkpoint blockers (ICB) targeting the PD-1/PD-L1 axis represent established therapies for many cancers. However, resistance occurs in most patients due to complex immune-suppressive ...

AbstractPurpose:. Hereditary colorectal cancer syndromes remain incompletely understood, with many cases lacking defined genetic causes. This study aimed to identify pathogenic mutations associated ...